[1]熊中山 罗素新 黄毕.Ⅺ因子抑制剂的研究进展[J].心血管病学进展,2025,(5):446.[doi:10.16806/j.cnki.issn.1004-3934.2025.05.015]
　XIONG Zhongshan,LUO Suxin,HUANG Bi.Factor Ⅺ Inhibitors[J].Advances in Cardiovascular Diseases,2025,(5):446.[doi:10.16806/j.cnki.issn.1004-3934.2025.05.015]
点击复制

Ⅺ因子抑制剂的研究进展()

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2025年5期
页码:
446
栏目:
综述
出版日期:
2025-05-25

文章信息/Info

Title:
Factor Ⅺ Inhibitors
作者:
熊中山 罗素新 黄毕
(重庆医科大学附属第一医院心血管内科,重庆 400016)
Author(s):
XIONG Zhongshan; LUO Suxin; HUANG Bi
(Department of Cardiology,The First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China)
关键词:
Ⅺ因子抑制剂; 抗凝药物; 血栓栓塞性疾病
Keywords:
Factor inhibitors; Anticoagulant drug; Thromboembolic disease
DOI:
10.16806/j.cnki.issn.1004-3934.2025.05.015
摘要:
抗凝药物在治疗和预防血栓栓塞性疾病中发挥着关键作用，通过干扰凝血级联反应的关键环节，有效控制血栓形成。然而，传统抗凝药物在减少血栓的同时，常伴有不同程度出血风险的增加。以凝血因子Ⅺ为靶点开发的新型抗凝血药—Ⅺ因子抑制剂可通过抑制Ⅺ因子来阻断凝血酶的生成，进而抑制血栓形成，且对生理性止血的影响较小，已成为最有潜力的新型抗凝血药之一。现对以Ⅺ因子为靶点的抗凝药物的病理生理机制及最新临床研究进展进行综述，以期为血栓栓塞性疾病的防治提供更多的选择。
Abstract:
Anticoagulant drugs play a crucial role in the treatment and prevention of thromboembolic diseases,effectively controlling thrombosis by interfering with key steps in the coagulation cascade. However,traditional anticoagulant drugs are often associated with an increased risk of bleeding to varying degrees while reducing thrombosis. Factor Ⅺ inhibitors,a new class of anticoagulants,target coagulation factor Ⅺ and block thrombin generation and inhibit thrombosis while having less impact on physiological hemostasis,which makes them as one of the most promising new anticoagulants. This article reviews the pathophysiological mechanisms and the latest clinical research progress of factor Ⅺ inhibitors,aiming to offer safer and more effective treatment options for patients with thromboembolic diseases.

参考文献/References:

[1] Long B,Gottlieb M. Direct oral anticoagulants versus conventional anticoagulants for deep vein thrombosis[J]. Acad Emerg Med,2023,30(9):974-976.

[2] Olie RH,Winckers K,Rocca B,et al. Oral anticoagulants beyond warfarin[J]. Annu Rev Pharmacol Toxicol,2024,64:551-575.

[3] Chan YH,Chan CY,Chen SW,et al. Comparisons of effectiveness and safety between on-label dosing,off-label underdosing,and off-label overdosing in Asian and non-Asian atrial fibrillation patients treated with rivaroxaban:a systematic review and meta-analysis of observational studies[J]. Europace,2023,25(10):euad288.

[4] Pokorney SD,Chertow GM,Al-Khalidi HR,et al.Apixaban for patients with atrial fibrillation on hemodialysis:a multicenter randomized controlled trial[J]. Circulation,2022,146(23):1735-1745.

[5] Elenjickal EJ,Travlos CK,Marques P,et al. Anticoagulation in patients with chronic kidney disease[J]. Am J Nephrol,2024,55(2):146-164.

[6] Cohen O,Santagata D,Ageno W. Novel horizons in anticoagulation:the emerging role of factor XI inhibitors across different settings[J]. Haematologica,2024,109(10):3110-3124.

[7] Greco A,Laudani C,Spagnolo M,et al. Pharmacology and clinical development of factor XI inhibitors[J]. Circulation,2023,147(11):897-913.

[8] de Caterina R,Prisco D,Eikelboom JW. Factor XI inhibitors:cardiovascular perspectives[J]. Eur Heart J,2023,44(4):280-292.

[9] Fredenburgh JC,Weitz JI. News at Ⅺ:moving beyond factor Ⅹa inhibitors[J]. J Thromb Haemost,2023,21(7):1692-1702.

[10] 刘少稳,魏勇. 重新认识心房颤动的心力衰竭并发症[J]. 临床心血管病杂志,2024,40(11):867-870.

[11] Goodman SG,Roy D,Pollack CV Jr,et al. Current gaps in the provision of safe and effective anticoagulation in atrial fibrillation and the potential for factor Ⅺ-directed therapeutics[J]. Crit Pathw Cardiol,2024,23(2):47-57.

[12] Dong Z,Hashizume K,Friedrichs F,et al. Pharmacokinetics and pharmacodynamics of the factor XIa-inhibiting antibody osocimab in healthy male East Asian volunteers:results from two phase 1 studies[J]. Pharmacol Res Perspect,2024,12(5):e70012.

[13] Lip GYH,Proietti M,Potpara T,et al. Atrial fibrillation and stroke prevention:25 years of research at EP Europace journal[J]. Europace,2023,25(9):euad226.

[14] Koulas I,Spyropoulos AC. A review of FⅪa inhibition as a novel target for anticoagulation[J]. Hamostaseologie,2023,43(1):28-36.

[15] Piccini JP,Caso V,Connolly SJ,et al. Safety of the oral factor Ⅺa inhibitor asundexian compared with apixaban in patients with atrial fibrillation(PACIFIC-AF):a multicentre,randomised,double-blind,double-dummy,dose-finding phase 2 study[J]. Lancet,2022,399(10333):1383-1390.

[16] Asundexian Phase 3 AF Study Halted for Lack of Efficacy[EB/OL]. (2023-11-20)[2024-10-10]. https://www.medscape.com/viewarticle/998665.

[17] Presume J,Ferreira J,Ribeiras R. Factor Ⅺ inhibitors:a new horizon in anticoagulation therapy[J]. Cardiol Ther,2024,13(1):1-16.

[18] Passacquale G,Sharma P,Perera D,et al. Antiplatelet therapy in cardiovascular disease:current status and future directions[J]. Br J Clin Pharmacol,2022,88(6):2686-2699.

[19] Wichaiyo S,Parichatikanond W,Visansirikul S,et al.Determination of the potential clinical benefits of small molecule factor Ⅺa inhibitors in arterial thrombosis[J]. ACS Pharmacol Transl Sci,2023,6(7):970-981.

[20] Rao SV,Kirsch B,Bhatt DL,et al. A multicenter,phase 2,randomized,placebo-controlled,double-blind,parallel-group,dose-finding trial of the oral factor Ⅺa inhibitor asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction[J]. Circulation,2022,146(16):1196-1206.

[21] Gibson CM,Bahit MC,Mehran R,et al. Oral factor xia inhibitor milvexian after a recent acute coronary syndrome:rationale and design of the phase 3(Librexia ACS)[J]. Am Heart J,2025,285:21-28.

[22] Prisco D,Canfora M,Mazzetti M,et al. Factor Ⅺ inhibitors:perspectives in primary and secondary prevention of ischemic stroke[J]. Intern Emerg Med,2024,19(7):1807-1819.

[23] Shoamanesh A,Mundl H,Smith EE,et al. Factor Ⅺa inhibition with asundexian after acute non-cardioembolic ischaemic stroke(PACIFIC-Stroke):an international,randomised,double-blind,placebo-controlled,phase 2b trial[J]. Lancet,2022,400(10357):997-1007.

[24] Sharma M,Molina CA,Toyoda K,et al. Safety and efficacy of factor Ⅺa inhibition with milvexian for secondary stroke prevention(AXIOMATIC-SSP):a phase 2,international,randomised,double-blind,placebo-controlled,dose-finding trial[J]. Lancet Neurol,2024,23(1):46-59.

[25] A phase 3,randomized,double-blind,parallel-group,placebo-controlled study to demonstrate the efficacy and safety of milvexian,an oral factor xia inhibitor,for stroke prevention after an acute ischemic stroke or high-risk transient ischemic attack:NCT05702034[R/OL]. clinicaltrials.gov,2025[2025-03-18]. https://clinicaltrials.gov/study/NCT05702034.

[26] A multicenter,international,randomized,placebo controlled,double-blind,parallel group and event driven phase 3 study of the oral fxia inhibitor asundexian(bay 2433334) for the prevention of ischemic stroke in male and female participants aged 18 years and older after an acute non-cardioembolic ischemic stroke or high-risk TIA:NCT05686070[R/OL]. clinicaltrials. gov,2025[2025-03-18]. https://clinicaltrials.gov/study/NCT05686070.

[27] Keeling NM,Wallisch M,Johnson J,et al.Pharmacologic targeting of coagulation factors Ⅻ and Ⅺ by monoclonal antibodies reduces thrombosis in nitinol stents under flow[J]. J Thromb Haemost,2024,22(5):1433-1446.

[28] Pfeffer MA,Kohs TCL,Vu HH,et al. Factor Ⅺ inhibition for the prevention of catheter-associated thrombosis in patients with cancer undergoing central line placement:a phase 2 clinical trial[J]. Arterioscler Thromb Vasc Biol,2024,44(1):290-299.

[29] Walsh M,Bethune C,Smyth A,et al. Phase 2 study of the factor Ⅺ antisense inhibitor IONIS-FXI RX in patients with ESRD[J]. Kidney Int Rep,2021,7(2):200-209.

[30] A phase 3,multicenter,randomized,double-blind,placebo-controlled,parallel-group study to evaluate the efficacy and safety of abelacimab in high-risk patients with atrial fibrillation who have been deemed unsuitable for oral anticoagulation(LILAC-TIMI 76):NCT05712200[R/OL]. clinicaltrials. gov,2025[2025-03-18]. https://clinicaltrials.gov/study/NCT05712200.

相似文献/References:

[1]魏倩 梁岩.新型口服抗凝药物与维生素K拮抗剂相关的脑出血风险对比[J].心血管病学进展,2020,(5):441.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.001]
　WEI Qian,LIANG Yan.Comparison of Risk of Related Intracerebral Hemorrhage Between Non-vitamin K Antagonist Oral Anticoagulants and Vitamin K Antagonists[J].Advances in Cardiovascular Diseases,2020,(5):441.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.001]
[2]曾谷雨 袁晋青.慢性冠状动脉综合征二级预防的抗血小板及抗凝治疗研究进展[J].心血管病学进展,2021,(12):1061.[doi:10.16806/j.cnki.issn.1004-3934.2021.12.002]
　ZENG Guyu,YUAN Jingqing.Antiplatelet and Antithrombotic Therapy for the Secondary Prevention of Chronic Coronary Syndrome[J].Advances in Cardiovascular Diseases,2021,(5):1061.[doi:10.16806/j.cnki.issn.1004-3934.2021.12.002]
[3]多力昆·木台力甫?阿布都赛米·艾尼 阿布都乃比·麦麦提艾力.青年女性患者心脏瓣膜的选择[J].心血管病学进展,2024,(6):489.[doi:10.16806/j.cnki.issn.1004-3934.202.06.003]
　Duolikun·Mutailifu,Abudusaimi·Aini,Abudunaibi·Maimaitiaili.Duolikun·Mutailifu1,Abudusaimi·Aini1,Abudunaibi·Maimaitiaili2[J].Advances in Cardiovascular Diseases,2024,(5):489.[doi:10.16806/j.cnki.issn.1004-3934.202.06.003]

更新日期/Last Update: 2025-06-26